Kissei Pharmaceutical (4547) Fundamentals 2026 — P/E 12.6x, Revenue Analysis | SniperIQ
Kissei Pharmaceutical (4547) is a JP-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥173.7B, trading at ¥4190.00 on the JPX. This SniperIQ fundamentals page covers Kissei Pharmaceutical's valuation (P/E 12.6x, P/B 0.8x), profitability (net margin 14.1%), revenue (¥97.4B in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Kissei Pharmaceutical's market cap?
Kissei Pharmaceutical (4547) has a market capitalization of approximately ¥173.7B, trading at ¥4190.00 on the JPX. Market cap moves with the live share price.
What is Kissei Pharmaceutical's P/E ratio?
Kissei Pharmaceutical's trailing twelve-month P/E ratio is 12.6x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Kissei Pharmaceutical?
Kissei Pharmaceutical runs a net profit margin of 14.1%, a gross margin of 47.0%, and an operating margin of -3.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Kissei Pharmaceutical generate?
Kissei Pharmaceutical reported revenue of ¥97.4B for fiscal year 2026, with net income of ¥13.8B and earnings per share (EPS) of 331.53. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Kissei Pharmaceutical pay a dividend?
Kissei Pharmaceutical offers a trailing dividend yield of about 3.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Kissei Pharmaceutical financially healthy?
Kissei Pharmaceutical carries a debt-to-equity ratio of 0.01x and a current ratio of 5.30x, with a market beta of -0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Kissei Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kissei Pharmaceutical (4547) the key facts are: market cap ¥173.7B, P/E 12.6x, revenue ¥97.4B, 52-week range 3500-5040. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Kissei Pharmaceutical's full fundamentals live
Get Kissei Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.